#USA #Boston #Morphic Medical #RESET #Terri Cooper

Morphic Medical Strengthens Its Board with Expert Leadership

Morphic Medical has made a significant addition to its leadership team with the appointment of Dr. Terri Cooper to its Board of Directors, a strategic move aimed at enhancing the company's focus on innovative treatment options for type 2 diabetes. As the pioneering creator of a unique medical device targeting the fundamental causes of this condition, Morphic Medical is poised to make powerful strides under Cooper's guidance.

Dr. Cooper is no stranger to the healthcare and life sciences industries, boasting an impressive 35 years of experience. Her extensive background includes pivotal roles across both public and private sectors globally, showcasing her expertise in navigating complex challenges associated with business operations, technology initiatives, and regulatory frameworks. Notably, Dr. Cooper served as a Principal at Deloitte's U.S. consulting practice, where she significantly contributed to the establishment of the Life Sciences R&D business. Her leadership has facilitated organizational transformations and financial restructures, effectively enhancing performance and innovation.

In her new role, Dr. Cooper expressed enthusiasm about joining Morphic Medical at a crucial juncture in metabolic health development. "I'm honored to join the Board of Morphic Medical at such a pivotal time in the evolution of metabolic health," she said. Her outlook aligns with the company's mission to develop less invasive, patient-centered solutions, recognizing them as essential innovations the healthcare system desperately needs.

Morphic Medical's President and CEO, Mike Gutteridge, emphasized the importance of Cooper’s expertise for the organization. He expressed, "Her deep understanding of strategy, regulatory navigation, and organizational transformation will be instrumental as we advance our U.S. STEP-1 clinical trial. We are also focused on building the clinical and commercial foundation for RESET®, our incision-free, endoscopic therapy intended for rapid weight reduction and significant metabolic improvement for patients with obesity and type 2 diabetes."

The company’s flagship treatment, RESET, represents a non-surgical alternative aimed at morbid obesity and other related health risks. While still under investigation and not available for commercial sale in the United States, RESET exemplifies Morphic Medical's commitment to challenging traditional medical approaches for chronic conditions. The company, founded in 2003 and headquartered in Boston, Massachusetts, aims to break existing barriers and enhance patient outcomes with innovative treatments.

As Morphic Medical strives to expand its initiatives under Dr. Cooper’s leadership, the healthcare community watches closely, anticipating the groundbreaking advancements they aim to achieve in addressing obesity and type 2 diabetes. The collaboration between experienced leadership and innovative technology presents a promising future in the pursuit of enhanced metabolic health solutions.

For further information about Morphic Medical and its ongoing projects, you can visit their website at morphicmedical.com or connect with them on Twitter and LinkedIn.